Maryland biopharmaceutical company purchases East Baltimore bioscience center

A Rockville, Maryland based biopharmaceutical company has purchased the East Baltimore bioscience nonprofit MdBio Foundation's 55,000-square-foot BioProcessing Center in East Baltimore.

The $8.2 million purchase by Emergent BioSolutions is meant to enhance its manufacturing infrastructure and will create up to 125 jobs over the next five years.

Emergent BioSolutions is best known for the manufacturing of BioThrax, which is the first and only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. The company also develops botulism, tuberculosis, typhoid, hepatitis B and Chlamydia vaccines and treatments, among other diseases.

Emergent BioSolutions employes over 600 employees worldwide, including more than 150 employees at its corporate headquarters in Rockville and at one of its product development sites in Gaithersburg.

The BioProcessing Center, completed in 1996 on land lease from the city of Baltimore, is near the Johns Hopkins University Bayview Research Campus. Following the facility's completion, MdBio Foundation negotiated a long-term lease with Bio Science Contract Production Corp., of New York, a contract biomanufacturing company.

BCSP was then sold to life sciences firm Cambrex Corp., of East Rutherford, N.J., in 2000. BCSP then assumed the lease on the facility. Cambrex was then sold in 2007 to biotechnology firm Lonza Group Ltd., of Basel, Switzerland.